Ryo Toyozawa

1PUBLICATIONS
19CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (1)

Sort by Publication Date:
|Mar 31, 2025
Randomized Phase III Study of EGFR Tyrosine Kinase Inhibitor and Intercalated Platinum-Doublet Chemotherapy for Non-Small Cell Lung Cancer Harboring EGFR Mutation.

Shintaro Kanda, Seiji Niho, Takayasu Kurata

Pageof 1

Frequent Collaborators

1 joint publications

Shintaro Kanda

1 joint publications

Seiji Niho

1 joint publications

Takayasu Kurata

1 joint publications

Shogo Nomura

1 joint publications

Yosuke Kawashima

1 joint publications

Eiji Iwama

1 joint publications

Toshihide Yokoyama

1 joint publications

Yasutaka Watanabe

1 joint publications

Hiroshi Tanaka

1 joint publications

Yutaka Fujiwara

Frequent Collaborators

1 joint publications

Shintaro Kanda

1 joint publications

Seiji Niho

1 joint publications

Takayasu Kurata

1 joint publications

Shogo Nomura

JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us

Top Related Videos

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on : Jun 26, 2019

7.9K
See more related videos

Top Related Videos

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on : Jun 26, 2019

7.9K
See more related videos